Mood & Mental Health

·

Study

COMP360 Psilocybin Halves Symptoms in 58% With Severe Depression

COMP360 Psilocybin Halves Symptoms in 58% With Severe Depression

Psilocybin mushrooms

What they found

In an open-label trial of 12 people with treatment-resistant depression, one 25 mg COMP360 dose halved symptoms in 58% at 12 weeks.

In an open-label trial of 12 people with treatment-resistant depression, one 25 mg COMP360 dose halved symptoms in 58% at 12 weeks.

The number

58% of patients after 12 weeks

How solid is it?

Early human

Early human

Evidence ladder: Lab dish → Animal → Early human → Strong human. Reviews summarize earlier research.

At a glance

Latin name

Compound

COMP360 psilocybin

COMP360 psilocybin

Sample size

12 participants

12 participants

Published in

American Journal of Psychiatry

American Journal of Psychiatry

Covered in Shroom Scan

Section

PSILOCYBIN & LEGISLATION

PSILOCYBIN & LEGISLATION

As it ran in Shroom Scan

An Open-Label Trial

An Open-Label Trial

In a trial with 12 participants facing severe treatment-resistant depression (TRD), a single 25 mg dose of COMP360 psilocybin reduced depressive symptoms by 50% or more in 58% of patients after 12 weeks. Remission was achieved in 25% of participants, with improvements linked to the intensity of their psilocybin experience.

In a trial with 12 participants facing severe treatment-resistant depression (TRD), a single 25 mg dose of COMP360 psilocybin reduced depressive symptoms by 50% or more in 58% of patients after 12 weeks. Remission was achieved in 25% of participants, with improvements linked to the intensity of their psilocybin experience.

Psilocybin Breakthrough, Gut-Healing Chanterelles, and Mushrooms vs. Plastic

Shroom Scan · Every Friday

Get Studies Like This, Translated, Every Week

Ten new studies a week, each boiled down to what it found and why it matters to you. Free, and one click to leave.